

NEW

Candioli Innovation

actea™

**The new frontier
in the field of otology
for dogs and cats**

actea™ OTO



ACTEA™ is a registered trademark by Candioli S.p.A.

www.candioli-vet.it

Candioli
PHARMA

External otitis in dogs and cats



External otitis represents one of the most **common causes for veterinary visits** (10-20%)²⁸

MAIN CAUSES^{3,13,24,28}

Atopic dermatitis
Food allergy
Foreign bodies
Seborrhoea

PREDISPOSING FACTORS^{3,13,24}

Abnormal ear canal configuration
Breed features
Poor ear hygiene



Photo source: Dr. Vercelli

COMPLICATING MICRO-ORGANISMS^{2,3,8,12,24}

Bacteria: *S. intermedius*, *Pseudomonas aeruginosa*, *Proteus vulgaris*
Yeasts: *Malassezia pachydermatis*

MAIN SYMPTOMS^{2,3,8,12,24}

Ear itching
Oedema and redness
Ceruminous and mucus-purulent secretions
Foul odour



LAS™ is a patented mixture* based on:

-  **Lactoferricin** – *hydrolysed lactoferrin*
-  **GPI** – glycerophosphoinositol lysine** – *semisynthetic derivative of sunflower lecithin*
-  **Verbascoside** (Dermasyr™)*** – *derived from plant stem cells (Syringa vulgaris)*

The **LAS™** components have the following properties upon topical application:

- ✓ Reduce **inflammation** and **itching**^{1,4,6,17,20,25,27,31}
- ✓ Moderate **skin dehydration** (TEWL - Trans Epidermal Water Loss)⁶
- ✓ Counteract **seborrhoea** and the subsequent development of **bacteria** and **yeasts** (data on file 2010)
- ✓ Exert **antibacterial**^{5,7,9,23} and **immunostimulatory activity**^{7,14,29}

At the ear level it is able to (data on file 2014):

-  Reduce the formation of **ceruminous secretions**
-  Decrease **desquamation** of the ear canal
-  Alleviate **itching, erythema and inflammation**
-  Counteract the **development of bacteria** (cocci and rods) and **yeasts** (*Malassezia*)

BEFORE



AFTER



Photo source: Dr. Vercelli



Use of ACTEA™ OTO topical product as adjuvant therapy for otitis externa in dogs (data on file 2014)

Field study conducted on 10 dogs suffering from recurring erythematous/ceruminous otitis by:
Dr. Antonella Vercelli DMV, dipl CESDerm and CESOfta, Dr Luisa Cornegliani DVM, dipl ECVD

1. Cerumenolytic activity: evident 10 minutes after application




2. Antibacterial and antiyeast activity



Average variation of the bacterial and Malassezia load - V1: before treatment - V2: 7dd - V3: 14dd - V4: 21dd

3. Otoscopic assessment of ear canal lesions



Average of scores obtained after otoscopic assessment of lesions - V1: before treatment - V2: 7dd - V3: 14dd - V4: 21dd

ACTEA™ OTO

Product features



What features must a good topical ear product have?

- ✓ **Easy** application
- ✓ **Well tolerated**
- ✓ **Effective** in removing ear wax
- ✓ **Active** on bacteria (gram+ and gram-) and *Malassezia*
- ✓ Able to **control** inflammation and erythema

The new solution

actea™
OTO

thanks to its
innovative formula



Essential bibliography

1. Bonina FP, Gimillaro D, Melandri F, Pressi G. Protective effect of topical formulations based on glycerophosphoinositol choline salt. *Dermatologia Ambulatoriale* 2006;4
2. Cafarchia C, et al. Valutazione quantitativa dei lieviti del genere *Malassezia* nel condotto uditivo di cani e gatti sani e con otite. *Veterinaria* 2006;20(3):27-31
3. Cole LK. Predisposing factors, primary causes and perpetuating factors of otitis. *NAVC Congress 2011 Proceedings*
4. Corda D, Falasca M. Glycerophosphoinositols as potential markers of Ras-induced transformation and novel second messengers. *Anticancer Research* 1996;16:1341-1350
5. Di Biase AM, et al. Effect of bovine lactoferricin on enteropathogenic *Yersinia* adhesion and invasion in HEp-2 cells. *Journal of Medical Microbiology* 2004;53:407-412
6. Falconi Klein E, Carrera C, Richelmi P. Evaluation of protective and dermo-balancing of a product for normalizing scalp psoriasis, by clinical trial use of polarized light camera and TEWL. *Biobasic Europe (Milan) University of Pavia, May 2003 (Report n. 020107-05F)*
7. Gifford JL, et al. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. *Cell Mol Life Sci* 2005;62(22):2588-98
8. Hariharan H, et al. Update on antimicrobial susceptibilities of bacterial isolates from canine and feline otitis externa. *Can Vet J* 2006;47:253-255
9. Istituto Profilattico e Farmaceutico Candioli & C. S.p.A. Antibacterial spectrum of Lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. *Data on file 2014 - patent pending*
10. Jenssen H. AntiHerpes simplex virus activity of lactoferrin-lactoferricin - an example of antiviral activity of antimicrobial protein/peptide. *Cell Mol Life Sci* 2005;62(24):3002-13
11. Korkina LG. Dermasyr sebum regulating activity. *Russian State Medical University, Moscow, Russia Data on file 2005*
12. Lyskova P, et al. Identification and antimicrobial susceptibility of bacteria and yeast isolated from healthy dogs and dogs with otitis externa. *J Vet Med* 2007;A54:559-563
13. Machicote Goth G. External ear disease in dogs and cats. *Veterinary Focus* 2011;21(3):2-9
14. Masuda A, et al. Study of lipid in the ear canal in canine otitis externa with *Malassezia pachydermatis*. *J Vet Med Sci* 2000;62(11):1177-1182
15. McCann KB, et al. The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. *Journal of Applied Microbiology* 2003;95:1026-1033
16. Mistry N, et al. The anti-papillomavirus activity of human and bovine lactoferricin. *Antiviral Res* 2007;75(3):258-65
17. Motolese A, Simonelli M. Effect of glycerophosphoinositol salt of choline 1% cream on mild-to-moderate inflammatory and allergic dermatitis. *Dermatological Experiences* 2008;10:135-40
18. Noxon JO. Five keys to successful management of otitis externa. *NAVC Conference 2011 Proceedings*
19. Oo TZ, et al. Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection. *J Antimicrob Chemother* 2010 doi:10.1093/jac/dkq106
20. Pastore S, et al. Plant polyphenols regulate chemokine expression and tissue repair in human keratinocytes through interaction with cytoplasmic and nuclear components of epidermal growth factor receptor system. *Antioxidants and Redox Signaling* 2012;16(4):314-328
21. Pastore S, Korkina LG, Dal Toso R. Anti-inflammatory properties of naturally occurring biotechnologically produced phenylpropanoid glycosides. *Laboratory of tissue engineering and skin pathophysiology, Rome, Italy, 2009 data on file*
22. Pazzaglia M, Tosti A. Efficacy evaluation of a treatment with a glycerophosphoinositol choline lenitive lotion by scalp dermoscopy. *Department of Specialistic and Experimental Clinical Medicine-Unit of Dermatological Clinic, Alma Mater Studiorum University of Bologna, Jan 2007*
23. Sanchez-Gomez S, et al. Structural featuring governing the activity of lactoferricin-derived peptides that act in synergy with antibiotics against *Pseudomonas aeruginosa* in vitro and in vivo. *Antimicrobial Agents and Chemotherapy* 2011;55(1):218-228
24. Scarampella F. Eziopatogenesi e approccio clinico all'otite esterna del cane. *Quaderni di Dermatologia* 2005;10(1):5-10
25. Shestakov A, et al. Lactoferricin but not lactoferrin inhibit herpes simplex virus type 2 infection in mice. *Antiviral Res* 2012;93(3):340-5
26. Vercelli A, Cornegliani L. Report Studio Clinico Pilota: Prodotto topico ACTEA™ OTO Candioli come coadiuvante del trattamento dell'otite esterna del cane. *Data on file 2014*
27. Yahagi S, Izutsu Y, Okano Y, Pressi G, Dal Toso R, Masaki H. Glycerophosphoinositol is a novel modulator of cytosolic phospholipase A2 (cPLA2): its anti-inflammatory effects and a possible mechanism. *25th IFSCC Congress, Barcelona, 6-9 October 2008*
28. Zur G, et al. The association between the signalment, common causes of canine otitis externa and pathogens. *J Small Anim Pract* 2011;52:254-258
29. In vitro evaluation of the irritation and anti-inflammatory potential of a topical cosmeceutic active. *Data on file 2003*
30. Patch-test with GPI lysine in healthy voluntary subjects. *Data on file 2009*
31. Photo-patching test with GPI choline in healthy voluntary subjects. *Data on file 2005*
32. Verbascoside Anti-Malassezia furfur activity. *Data on file 2010*



actea™

OTO

The new frontier in the field of otology for dogs and cats

- **Cerumenolytic** and **keratolytic effectiveness**
- **Adjuvant action** in recurring ceruminous otitis
- **Good tolerability** and **ease of application**



Product sheet

INDICATIONS

Emulsion for otological use in cats and dogs indicated as an adjunct in treating external ear conditions characterised by itching, redness, changes in bacterial and fungal flora, associated with excessive production of cerumen and foul odour. Thanks to its cerumenolytic, soothing and sanitising properties, **Actea™ Oto** may even be used to prevent ear infections of various origins in predisposed subjects.

Actea™ Oto is generally recommended in all situations where the physiological conditions of the ear canal need to be restored.

COMPOSITION

Aqua (water), Lactoferin hydrolizate, Propylene glycol, Glycerin, Glycerophosphoinositol Lysine, Syringa vulgaris (Lilac) leaf cell culture extract, Maltodextrin, Tocopherol, Arginine, Triclosan, Oleic acid, Carbomer, Polysorbate 80, Benzyl alcohol, Ethylhexylglycerin, Phenoxyethanol.

DIRECTIONS FOR USE

Apply **4-8 drops per ear**, depending on the size of the animal size, **twice a day**. Delicately massage the base of the ear to allow the product to be adequately distributed inside. Repeat the operation for **at least ten consecutive days** until the ear is clean and free of cerumen and secretions.